Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:clinicalTrials |
Alzheimer's imaging studies
|
| gptkbp:employeeCount |
50-100
|
| gptkbp:focusArea |
Alzheimer's disease
|
| gptkbp:foundedIn |
2005
|
| gptkbp:founder |
gptkb:David_A._Kessler
|
| gptkbp:headquarters |
gptkb:Philadelphia,_Pennsylvania
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avid Radiopharmaceuticals
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:lensType |
PET imaging agent
|
| gptkbp:market |
Neurodegenerative diseases
|
| gptkbp:partnerships |
Academic institutions
|
| gptkbp:products |
gptkb:Flutemetamol
Florbetapir Florbetaben |
| gptkbp:regulatoryCompliance |
FDA_approval
|
| gptkbp:researchAndDevelopment |
Innovative imaging agents
|
| gptkbp:specializesIn |
Radiopharmaceuticals
|
| gptkbp:website |
www.avidrp.com
|